Tovinontrine Phase 2 Trial Results Have Been Presented

Cardurion Pharmaceuticals showed a reduction in heart failure biomarkers during a 12-week clinical study.

Updated on Oct. 11, 2026 in Heart Disease

Tovinontrine Phase 2 Trial Results Have Been Presented

Live Poll

Do you believe new pharmaceutical research is effectively improving treatment options for chronic heart failure?

Cardurion Pharmaceuticals has released Phase 2 clinical trial results for its oral drug tovinontrine, which is designed to treat chronic heart failure. The study found that the phosphodiesterase-9 inhibitor successfully reduced NT-proBNP biomarker levels in patients.

Why it matters

The medication aims to improve heart function by enhancing natriuretic peptide signaling in patients, addressing a pathway often disrupted in those with chronic heart failure. This development represents a potential new approach to managing the condition for the 6.7 million American adults currently living with the diagnosis.

Clinical trials showed NT-proBNP reduction using 2.5 mg and 25 mg doses over 12 weeks, while the 50 mg dose demonstrated no benefit. The studies involved 529 participants with reduced ejection fraction and 277 with preserved ejection fraction.

The players

Cardurion Pharmaceuticals

This Burlington, Massachusetts-based biotechnology company is the first to bring a PDE9 inhibitor into clinical development for chronic heart failure.

The details

Tovinontrine functions as a phosphodiesterase-9 inhibitor and is administered alongside standard medical therapies to support cardiomyocyte signaling. While the treatment showed a favorable safety and tolerability profile, the reduction of heart failure biomarkers was not observed at the 50 mg BID dose level.

NT-proBNP biomarker decreases were first observed at week 2.
The clinical treatment period lasted for 12 weeks.
Phase 2 results were presented at a scientific meeting on October 11, 2026.

Health Landscape

This study follows a pattern established by the ongoing scientific exploration of the natriuretic peptide signaling pathway in cardiac health. By targeting PDE9, this trial marks a novel attempt to treat heart failure by pharmacologically enhancing this specific biological mechanism.

While the drug remains in clinical development, the positive results suggest a potential new treatment path for those with chronic heart failure. Patients should continue their current guideline-directed medical therapy until these studies progress toward regulatory approval.

The takeaway

Advancements in targeted therapies like tovinontrine demonstrate the industry's shift toward correcting specific disrupted signaling pathways in heart patients. Future research will focus on identifying optimal lower-dose treatments for those with heart failure and preserved ejection fraction.